211 related articles for article (PubMed ID: 32097684)
21. Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery.
Liu S; Ono RJ; Yang C; Gao S; Ming Tan JY; Hedrick JL; Yang YY
ACS Appl Mater Interfaces; 2018 Jun; 10(23):19355-19364. PubMed ID: 29757607
[TBL] [Abstract][Full Text] [Related]
22. HPMA-based polymeric conjugates in anticancer therapeutics.
Rani S; Gupta U
Drug Discov Today; 2020 Jun; 25(6):997-1012. PubMed ID: 32334073
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
24. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Mahmoudian M; Valizadeh H; Zakeri-Milani P
Drug Dev Ind Pharm; 2018 Oct; 44(10):1598-1605. PubMed ID: 29874944
[TBL] [Abstract][Full Text] [Related]
26. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
27. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction.
Rong J; Li P; Ge Y; Chen H; Wu J; Zhang R; Lao J; Lou D; Zhang Y
Colloids Surf B Biointerfaces; 2020 Feb; 186():110674. PubMed ID: 31855686
[TBL] [Abstract][Full Text] [Related]
28. Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations.
Chaudhary S; Gothwal A; Khan I; Srivastava S; Malik R; Gupta U
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():611-619. PubMed ID: 28024628
[TBL] [Abstract][Full Text] [Related]
29. A smart magnetic nanoplatform for synergistic anticancer therapy: manoeuvring mussel-inspired functional magnetic nanoparticles for pH responsive anticancer drug delivery and hyperthermia.
Sasikala AR; GhavamiNejad A; Unnithan AR; Thomas RG; Moon M; Jeong YY; Park CH; Kim CS
Nanoscale; 2015 Nov; 7(43):18119-28. PubMed ID: 26471016
[TBL] [Abstract][Full Text] [Related]
30. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma.
Korani M; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Nanomedicine; 2019 Aug; 20():102013. PubMed ID: 31103736
[TBL] [Abstract][Full Text] [Related]
32. Sialic Acid Engineered Prodrug Nanoparticles for Codelivery of Bortezomib and Selenium in Tumor Bearing Mice.
Rani S; Sahoo RK; Mahale A; Panchal K; Chaurasiya A; Kulkarni O; Kuche K; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Bioconjug Chem; 2023 Sep; 34(9):1528-1552. PubMed ID: 37603704
[TBL] [Abstract][Full Text] [Related]
33. Anti-proliferate and apoptosis triggering potential of methotrexate-transferrin conjugate encapsulated PLGA nanoparticles with enhanced cellular uptake by high-affinity folate receptors.
Parmar A; Jain A; Uppal S; Mehta SK; Kaur K; Singh B; Sandhir R; Sharma S
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):704-719. PubMed ID: 29745729
[TBL] [Abstract][Full Text] [Related]
34. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of dual-functional targeting probes for cancer theranostics based on iron oxide nanoparticles coated by centipede-like polymer connected with pH-responsive anticancer drug.
Zhao H; Li Z; Yang B; Wang J; Li Y
J Biomater Sci Polym Ed; 2015; 26(16):1178-89. PubMed ID: 26249213
[TBL] [Abstract][Full Text] [Related]
36. Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy.
Li D; Su T; Ma L; Yin F; Xu W; Ding J; Li Z
Eur J Med Chem; 2020 Aug; 199():112367. PubMed ID: 32474350
[TBL] [Abstract][Full Text] [Related]
37. Self-assembly and self-delivery nanodrug of bortezomib: a simple approach to achieve the trade-off between functionality and druggability.
Zhao F; Liu X; Dong A; Deng L; Wang W; Zhang J
J Mater Chem B; 2019 Dec; 7(47):7490-7493. PubMed ID: 31763663
[TBL] [Abstract][Full Text] [Related]
38. HPMA-based block copolymers promote differential drug delivery kinetics for hydrophobic and amphiphilic molecules.
Tomcin S; Kelsch A; Staff RH; Landfester K; Zentel R; Mailänder V
Acta Biomater; 2016 Apr; 35():12-22. PubMed ID: 26772526
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester.
Jäger E; Jäger A; Chytil P; Etrych T; Ríhová B; Giacomelli FC; Stěpánek P; Ulbrich K
J Control Release; 2013 Jan; 165(2):153-61. PubMed ID: 23178950
[TBL] [Abstract][Full Text] [Related]
40. Enhanced intracellular accumulation and cytotoxicity of bortezomib against liver cancer cells using N-stearyl lactobionamide surface modified solid lipid nanoparticles.
Mostafaei F; Hemmati S; Valizadeh H; Mahmoudian M; Sarfraz M; Abdi M; Torabi S; Baradaran B; Vosough M; Zakeri-Milani P
Int J Pharm; 2024 Jan; 649():123635. PubMed ID: 38000649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
